Drugs / VTP1000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06310291 | Aug 2024 → Nov 2026 expected | celiac disease | Barinthus Biotherapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VTP1000 | “A sentinel dosing approach will be followed, with the first 2 participants randomized to receive VTP1000 or placebo in a 1:1 ratio.” NCT06310291 ↗ |
| Modality | Peptide | “VTP-1000 is a gluten-derived (GLU) peptide immunotherapy” NCT06310291 ↗ |
| Route | Intramuscular | “Intramuscular (IM) injection” NCT06310291 ↗ |